


55

and patent applications mentioned herein are expressly incorporated by reference therein to the same extent as though each were individually so incorporated.

Having thus described exemplary embodiments of the present invention, it should be noted by those skilled in the art that the within disclosures are exemplary only and that various other alternatives, adaptations, and modifications may be made within the scope of the present invention. Accordingly, the present invention is not limited to the specific embodiments as illustrated herein, but is only limited by the following claims.

What is claimed is:

1. A compound having the structural formula A or B




wherein R^1 and R^2 are each independently a hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, amino, substituted or unsubstituted alkylamino or substituted or unsubstituted alkylaryl, and

wherein R^3 is a substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted acyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkylaryl, sulfonyl, or substituted or unsubstituted alkylsulfonyl,

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1, wherein R^1 and R^2 are each independently $-H$, $-Cl$, $-Br$, $-CF_3$, $-OCH_3$, or $-OCF_3$.

3. The compound of claim 1, wherein R^3 is $-CH_2CH_3$, $-CH_2CH(CH_3)_2$, $-C(CH_3)_3$, $-CH_2C_6H_5$, $-(CH_2)_5CH_3$,



$-CH_2CH_2C=CH_2$, or $-CH_2CH_2OCH_2C_6H_5$.

4. A compound selected from the following group
N-(3,4-dichlorophenyl)-N'-(1-isopropyl-4,5-dioxoimidazolidin-2-ylidene)-guanidine (3);

56

N-(3,4-dichlorophenyl)-N'-ethoxycarbonyl-N''-(1-isopropyl-4,5-dioxoimidazolidin-2-ylidene)-guanidine (3a);
N-(3,4-dichlorophenyl)-N'-(isobutoxycarbonyl)-N''-(1-isopropyl-4,5-dioxoimidazolidin-2-ylidene)-guanidine (3b);

N-(3,4-dichlorophenyl)-N'-(1-isopropyl-4,5-dioxoimidazolidin-2-ylidene)-N''-(tert-butoxycarbonyl)-guanidine (3c);

N-(3,4-dichlorophenyl)-N'-(benzyloxycarbonyl)-N''-(1-isopropyl-4,5-dioxoimidazolidin-2-ylidene)-guanidine (3d);

N-(3,4-dichlorophenyl)-N'-(1-hexyloxycarbonyl)-N''-(1-isopropyl-4,5-dioxoimidazolidin-2-ylidene)-guanidine (3e);

N-(3,4-dichlorophenyl)-N'-(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl-N''-(1-isopropyl-4,5-dioxoimidazolidin-2-ylidene)guanidine (3f);

N-(3,4-dichlorophenyl)-N'-(3-butenyloxycarbonyl)-N''-(1-isopropyl-4,5-dioxoimidazolidin-2-ylidene)-guanidine (3g);

N-(3,4-dichlorophenyl)-N'-(2-benzyloxyethoxycarbonyl)-N''-(1-isopropyl-4,5-dioxoimidazolidin-2-ylidene)-guanidine (3h);

N-[1-(3,4-dichlorophenyl)-4,5-dioxo-4,5-dihydro-1H-imidazol-2-yl]-N'-isopropylguanidine (4);

N-[1-(3,4-dichlorophenyl)-4,5-dioxoimidazolidin-2-ylidene]-N'-isopropyl-N''-(ethylcarbonyl)guanidine (4a);

N-[1-(3,4-dichlorophenyl)-4,5-dioxoimidazolidin-2-ylidene]-N'-isopropyl-N''-(isobutyloxycarbonyl)guanidine (4b);

N-[1-(3,4-dichlorophenyl)-4,5-dioxoimidazolidin-2-ylidene]-N'-isopropyl-N''-(tert-butoxycarbonyl)guanidine (4c);

N-[1-(3,4-dichlorophenyl)-4,5-dioxoimidazolidin-2-ylidene]-N'-isopropyl-N''-(benzyloxycarbonyl)guanidine (4d);


N-[1-(3,4-dichlorophenyl)-4,5-dioxoimidazolidin-2-ylidene]-N'-isopropyl-N''-(1-hexyloxycarbonyl)guanidine (4e); and

N-[1-(3,4-dichlorophenyl)-4,5-dioxoimidazolidin-2-ylidene]-N'-isopropyl-N''-(3-butenyloxycarbonyl)guanidine (4g).

5. A method of treating, preventing, or inhibiting malaria or a disease or disorder associated with malaria or a *Plasmodium* parasite which comprises administering a therapeutically effective amount of at least one compound of claim 1 to a subject in need thereof.

6. The method of claim 5, wherein R^1 and R^2 are each independently $-H$, $-Cl$, $-Br$, $-CF_3$, $-OCH_3$, or $-OCF_3$.

7. The method of claim 5, wherein R^3 is $-CH_2CH_3$, $-CH_2CH(CH_3)_2$, $-C(CH_3)_3$, $-CH_2C_6H_5$, $-(CH_2)_5CH_3$,



$-CH_2CH_2C=CH_2$, or $-CH_2CH_2OCH_2C_6H_5$.

8. The method of claim 5, wherein the compound is administered intramuscularly, orally, or transdermally.